• Wed news: Novo and Viking heat up MASH space. New Pfizer R&D chief. Trump and the Biosecure Act. Sage Huntington’s prospect flunks trial. Dr. Oz to run CMS. See more on our front page

Fly on the wall, buyout chatter…

Quote
























anonymous said:
Like you even know anything. Stock will be $100 in a year based on growth potential
Click to expand...
Well it’s called chatter for a reason… your not yet approved and PDUFA date is mid 2025… there is modest growth till you launch with full year impact in 2026. Buyouts on phase 3 tradings in advance of approval is not uncommon but a risk for suitor… at current levels your stock price reflect supposition… and the fact there’s no wrinkles in NDA filing.
 




anonymous said:
Well it’s called chatter for a reason… your not yet approved and PDUFA date is mid 2025… there is modest growth till you launch with full year impact in 2026. Buyouts on phase 3 tradings in advance of approval is not uncommon but a risk for suitor… at current levels your stock price reflect supposition… and the fact there’s no wrinkles in NDA filing.
Click to expand...
Not sure why they would sell at $78 a share. The stock will be double that in two years
 








Top Bottom
Back
Quote